Search

Your search keyword '"Ouzan D."' showing total 448 results
Start Over Author "Ouzan D."
448 results on '"Ouzan D."'

2. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Author

Mangia, A., primary, Fagiuoli, S., additional, Di Marco, V., additional, Shafran, S., additional, Khalili, M., additional, Milligan, S., additional, Papatheodoridis, G., additional, Ouzan, D., additional, Rosati, S., additional, Ramji, A., additional, Teti, E., additional, Garcia-Retortillo, M., additional, Hernandez, F. Andres Perez, additional, Wong, A., additional, Fraser, C., additional, Rodriguez-Tajes, S., additional, Mutiloa, E. Jimenèz, additional, Amado, L. Enrique Morano, additional, O'Loan, J., additional, Campanale, F., additional, Macedo, G., additional, Milella, M., additional, Brixko, C., additional, Buti, M., additional, Veloz, M. Guerra, additional, Ranieri, Roberto, additional, Borgia, S., additional, Bascia, A., additional, Rodriguez, C.M. Fern, additional, Conway, B., additional, de Ledinghen, V., additional, Fenech, M., additional, Ryan, P., additional, Maida, I., additional, Martins, A., additional, Scherbakovsky, S., additional, Ntalla, I., additional, Hernandez, C., additional, Vanstraelen, K., additional, and Turnes, J., additional

Published
2023
Full Text
View/download PDF

3. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

Author

Mangia, A, Milligan, S, Khalili, M, Fagiuoli, S, Shafran, S, Carrat, F, Ouzan, D, Papatheodoridis, G, Ramji, A, Borgia, S, Wedemeyer, H, Losappio, R, Perez-Hernandez, F, Wick, N, Brown, R, Lampertico, P, Doucette, K, Ntalla, I, Ramroth, H, Mertens, M, Vanstraelen, K, Turnes, J, Mangia A., Milligan S., Khalili M., Fagiuoli S., Shafran S. D., Carrat F., Ouzan D., Papatheodoridis G., Ramji A., Borgia S. M., Wedemeyer H., Losappio R., Perez-Hernandez F., Wick N., Brown R. S., Lampertico P., Doucette K., Ntalla I., Ramroth H., Mertens M., Vanstraelen K., Turnes J., Mangia, A, Milligan, S, Khalili, M, Fagiuoli, S, Shafran, S, Carrat, F, Ouzan, D, Papatheodoridis, G, Ramji, A, Borgia, S, Wedemeyer, H, Losappio, R, Perez-Hernandez, F, Wick, N, Brown, R, Lampertico, P, Doucette, K, Ntalla, I, Ramroth, H, Mertens, M, Vanstraelen, K, Turnes, J, Mangia A., Milligan S., Khalili M., Fagiuoli S., Shafran S. D., Carrat F., Ouzan D., Papatheodoridis G., Ramji A., Borgia S. M., Wedemeyer H., Losappio R., Perez-Hernandez F., Wick N., Brown R. S., Lampertico P., Doucette K., Ntalla I., Ramroth H., Mertens M., Vanstraelen K., and Turnes J.

Abstract

Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. Methods: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. Results: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P =.002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). Conclusions: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.

Published
2020

5. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

Author

Mangia, A. Milligan, S. Khalili, M. Fagiuoli, S. Shafran, S.D. Carrat, F. Ouzan, D. Papatheodoridis, G. Ramji, A. Borgia, S.M. Wedemeyer, H. Losappio, R. Pérez-Hernandez, F. Wick, N. Brown, R.S., Jr. Lampertico, P. Doucette, K. Ntalla, I. Ramroth, H. Mertens, M. Vanstraelen, K. Turnes, J.

Abstract

Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. Methods: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. Results: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P =.002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). Conclusions: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis. © 2020 The Authors. Liver International published by John Wiley & Sons Ltd

Published
2020

6. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial

Author

FERENCI, P, ASSELAH, T, FOSTER, G R, ZEUZEM, S, SARRAZIN, C, MORENO, C, OUZAN, D, MAEVSKAYA, M, CALINAS, F, MORANO, L E, CRESPO, J, DUFOUR, J-F, BOURLIERE, M, AGARWAL, K, FORTON, D, SCHUCHMANN, M, ZEHNTER, E, NISHIGUCHI, S, OMATA, M, STERN, J, DATZENKO, Y, SCHERER, J, and QUINSON, A M

Published
2013

8. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. (Liver Disease)

Author

Renou, C., Halfon, P., Pol, S., Cacoub, P., Jouve, E., Bronowicki, J.P., Arpurt, J.P., Rifflet, H., Picon, M., Causse, X., Canva, V., Denis, J., Tran, A., Bourliere, M., Ouzan, D., Pariente, A., Dantin, S., Alric, L., Cartier, V., Reville, M., and Caillat-Zucman, S.

Subjects
Hepatitis C virus -- Physiological aspects -- Research -- Genetic aspects, Liver diseases -- Causes of -- Genetic aspects -- Research, Histology, Pathological -- Research -- Genetic aspects -- Physiological aspects, Health, Physiological aspects, Research, Genetic aspects, Causes of
Abstract

Objective: A significant proportion of individuals with chronic hepatitis C virus (HCV) infection hove persistently normal alanine aminotransferase (ALT) levels. Although data are controversial, such patients usually have weaker histological [...]

Published
2002

14. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study

Author

Portal, I., Bourlière, M., Halfon, P., De Lédinghen, V., Couzigou, P., Bernard, P. H., Blanc, F., Caroli-Bosc, F., Arpurt, J. P., Vetter, D., Mathieu-Chandelier, C., Chazouillères, O., Thiefin, G., Pol, S., Sogni, P., Abergel, A., Bailly, F., Picon, M., Debonne, J. M., Zamora, C., Alleman, I., Moreau, X., Doll, F., Eugène, C., Ducloux, S., Larrey, D., Ouzan, D., Grimaud, J. C., Gouvernet, J., Botti, G., Gérolami, V., Khiri, H., Gérolami, A., Gauthier, A. P., and Botta-Fridlund, D.

Published
2003

23. Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Author

Halfon, P., primary, Scholtes, C., additional, Izopet, J., additional, Larrat, S., additional, Penaranda, G., additional, Trimoulet, P., additional, Zoulim, F., additional, Alric, L., additional, Metivier, S., additional, Bourliere, M., additional, Leroy, V., additional, Ouzan, D., additional, de Ledinghen, V., additional, Mohamed, S., additional, Thelu, M.-A., additional, and Abravanel, F., additional

Published
2017
Full Text
View/download PDF

24. Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients

Author

Ouzan, D., primary, Penaranda, G., additional, Lefolgoc, G., additional, Antoni, M., additional, Delasalle, P., additional, Fontanges, T., additional, Cerdan, P., additional, Toulemonde, P., additional, Bresson-Hadni, S., additional, Beorchia, S., additional, Boyer, N., additional, Hanslik, B., additional, Joly, H., additional, Liautard, J., additional, Baesjou, S., additional, Bonny, C., additional, Halfon, P., additional, Renou, C., additional, and Bourliere, M., additional

Published
2017
Full Text
View/download PDF

25. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Author

PASSARIELLO, Nicola, Mangia A, Tivadar Bányai, De Bartolomeo G, Gervain J, Habersetzer F, MulkayJ P, Ouzan D, Parruti G., Passariello, Nicola, Mangia, A, Tivadar, Bányai, De Bartolomeo, G, Gervain, J, Habersetzer, F, Mulkayj, P, Ouzan, D, and Parruti, G.

Subjects
virus diseases, hepatitis C, abbreviated therapy, peginterferon alfa/ribavirin
Abstract

Background & Aims PROPHESYS is a large, multinational, non-interventional prospective cohort study of chronic hepatitis C patients treated with peginterferon alfa/ribavirin. This subanalysis assesses rates of premature treatment discontinuation stratified by on-treatment virological response (VR). Methods This PROPHESYS subanalysis is restricted to treatment-naive, hepatitis C virus (HCV) genotype (G)1/2/3 mono-infected patients who received peginterferon alfa-2a (40KD)/ribavirin with intended treatment duration of 48 (G1) or 24 weeks (G2/3). Early virological responses were classified into four mutually exclusive categories [rapid VR (RVR), complete early VR (cEVR), partial EVR (pEVR), no RVR/EVR], using standard criteria. Results The likelihood for shortening treatment owing to good efficacy was highest among patients with an RVR and HCV RNA ≤400 000 IU/ml (G1 10.0%; G2/3 5.8%) whereas for poor efficacy, it was highest in G1 non-RVR/EVR patients with HCV RNA >400 000 IU/ml (56.6%). Factors significantly associated with early treatment discontinuation as a result of good efficacy in G1 patients included RVR vs. no RVR/EVR and, at baseline, lower HCV RNA, lower FIB-4 score, HCV infection via injection drug use. For G2/3 patients, factors included lower baseline HCV RNA and G2 vs. G3 infection. Most patients started with the recommended peginterferon alfa-2a dose, but a high proportion received a higher-than-recommended ribavirin dose. Conclusions Despite international guidelines, few physicians used early viral kinetics to abbreviate treatment. Therefore, relatively few patients with an RVR and low baseline HCV RNA abbreviated treatment. In addition, there were deviations in ribavirin starting doses, suggesting that physicians tailor treatment according to local guidelines or previous experience.

Published
2013

26. Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

Author

Marcellin, P., primary, Xie, Q., additional, Paik, S.W., additional, Flisiak, R., additional, Piratvisuth, T., additional, Petersen, J., additional, Asselah, T., additional, Cornberg, M., additional, Ouzan, D., additional, Foster, G.R., additional, Papatheodoridis, G.V., additional, Messinger, D., additional, Regep, L., additional, Bakalos, G., additional, Alshuth, U., additional, and Wedemeyer, H., additional

Published
2016
Full Text
View/download PDF

27. Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France

Author

Ouzan, D., primary, Penaranda, G., additional, Delasalle, P., additional, Renou, C., additional, Hanslik, B., additional, Antoni, M., additional, Toulemonde, P., additional, Fontanges, T., additional, Bresson-Hadni, S., additional, Halfon, P., additional, Boyer, N., additional, Liautard, J., additional, Baesjou, S., additional, Bonny, C., additional, Cerdan, P., additional, and Bourlière, M., additional

Published
2016
Full Text
View/download PDF

28. Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

Author

Allaire, M., primary, Bourcier, V., additional, Layese, R., additional, Corvi, L., additional, Petrov-Sanchez, V., additional, Marcellin, P., additional, Guyader, D., additional, Larrey, D., additional, De Lédinghen, V., additional, Ouzan, D., additional, Zoulim, F., additional, Roulot, D., additional, Tran, A., additional, Bronowicki, J.-P., additional, Zarski, J.-P., additional, Riachi, G., additional, Calès, P., additional, Péron, J.-M., additional, Alric, L., additional, Bourlière, M., additional, Mathurin, P., additional, Nahon, P., additional, and Roudot-Thoraval, F., additional

Published
2016
Full Text
View/download PDF

29. AVDLIB 2: News Direct-Acting Antiviral (DDA) in HCV Patients with Advanced Liver Disease. Final Results of a the Second Multicenter Prospective Observational Study in Real Life Practice in France

Author

Ouzan, D., primary, Penaranda, G., additional, Delasalle, P., additional, Renou, C., additional, Antoni, M., additional, Toulemonde, P., additional, Halfon, P., additional, Bresson-Hadni, S., additional, Liautard, J., additional, and Bourlière, M., additional

Published
2016
Full Text
View/download PDF

30. Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort)

Author

Bagnis, C.I., primary, Layese, R., additional, Divard, G., additional, Cacoub, P., additional, Bourcier, V., additional, Corvi, L., additional, Petro-Sanchez, V., additional, Marcellin, P., additional, Guyader, D., additional, Pol, S., additional, Larrey, D., additional, De Ledingen, V., additional, Ouzan, D., additional, Zoulim, F., additional, Deray, G., additional, Roudot-Thoraval, F., additional, and Nahon, P., additional

Published
2016
Full Text
View/download PDF

31. The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Author

Bureau, C., primary, Thabut, D., additional, Layese, R., additional, Bourcier, V., additional, Corvy, L., additional, Petrov-Sanchez, V., additional, Marcellin, P., additional, Guyader, D., additional, Pol, S., additional, Larrey, D., additional, Zoulim, F., additional, Roulot, D., additional, De Ledinghen, V., additional, Ouzan, D., additional, Tran, A., additional, Bronowicki, J.-P., additional, Riachi, G., additional, Cales, P., additional, Peron, J.-M., additional, Alric, L., additional, Bourliere, M., additional, Mathurin, P., additional, Zarski, J.-P., additional, Roudot-Thoraval, F., additional, and Nahon, P., additional

Published
2016
Full Text
View/download PDF

32. Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)

Author

Costentin, C., primary, Layese, R., additional, Bourcier, V., additional, Corvi, L., additional, Petro-Sanchez, V., additional, Marcellin, P., additional, Guyader, D., additional, Pol, S., additional, Larrey, D., additional, de Ledinghen, V., additional, Ouzan, D., additional, Zoulim, F., additional, zarski, J.P., additional, Roulot, D., additional, Tran, A., additional, Bronowicki, J.-P., additional, Riachi, G., additional, Cales, P., additional, Péron, J.M., additional, Alric, L., additional, Bourlière, M., additional, Mathurin, P., additional, Sutton, A., additional, Letouze, E., additional, Zucman-Rossi, J., additional, Roudot-Thoraval, F., additional, and Nahon, P., additional

Published
2016
Full Text
View/download PDF

34. New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)

Author

Thabut, D., primary, Bureau, C., additional, Layese, R., additional, Bourcier, V., additional, Corvy, L., additional, Petrov-Sanchez, V., additional, Marcellin, P., additional, Guyader, D., additional, Pol, S., additional, Larrey, D., additional, Zoulim, F., additional, Roulot, D., additional, De Ledinghen, V., additional, Ouzan, D., additional, Tran, A., additional, Bronowicki, J.-P., additional, Riachi, G., additional, Cales, P., additional, Peron, J.-M., additional, Alric, L., additional, Bourliere, M., additional, Mathurin, P., additional, Zarski, J.-P., additional, Roudot-Thorava, P., additional, and Nahon, P., additional

Published
2016
Full Text
View/download PDF

35. Prévalence séro-virologique du virus de l hépatite E au sein d'une cohorte de malades porteurs d'une hépatite C chronique du sud-est de la France

Author

Renou, Catherine, Tesse, Sophie, Nicand, Elisabeth, Roque Afonso, AM., Pavio, Nicole, Pénaranda, G., Bourlière, M., Anty, R., Ouzan, D., Gerolami, R., Botta, D., Halfon, P., Centre Hospitalier Général de Hyères (CHG), Hôpital Inter Armées Begin, Hôpital d'instruction des armées du Val-de-Grâce, Virologie UMR1161 (VIRO), Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-École nationale vétérinaire d'Alfort (ENVA), AFEF. Labo/service de l'auteur, Ville service., and École nationale vétérinaire d'Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)

Subjects
[SDV]Life Sciences [q-bio], Séro-virologie, hépatite E, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

36. P0822 : Safety And efficacy of sofosbuvir containing regimens for hepatitis C: Community treatment of a real world population with advanced liver fibrosis

Author

Ouzan, D., primary, Fontanges, T., additional, Pénaranda, G., additional, Delasalle, P., additional, Antoni, M., additional, Bresson-Hadni, S., additional, Cerdan, P., additional, Beorchia, S., additional, Toulemonde, P., additional, Boyer, N., additional, Castelnau, C., additional, Jacques, J.-P., additional, Serge, B., additional, Bonny, C., additional, Boussoukouya, S., additional, Joly, H., additional, and Hanslik, B., additional

Published
2015
Full Text
View/download PDF

37. P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey

Author

Garioud, A., primary, Cadranel, J.-F., additional, Pauwels, A., additional, Thévenot, T., additional, Louvet, A., additional, Dao, T., additional, Sogni, P., additional, Talbodec, N., additional, Bureau, C., additional, Thabut, D., additional, Elkrief, L., additional, Jouannaud, V., additional, Macaigne, G., additional, Bernard-Chabert, B., additional, Lison, H., additional, Alric, L., additional, Carbonnel, N., additional, Pageaux, G.-P., additional, Bettan, L., additional, Labadie, H., additional, Nahon, P., additional, Bader, R., additional, Zarski, J.-P., additional, Abergel, A., additional, Pol, S., additional, Pariente, A., additional, Amiot, X., additional, Mathurin, P., additional, Ollivier-Hourmand, I., additional, Bismuth, M., additional, Dupont, K., additional, Rosa-Hézode, I., additional, Lesgourgues, B., additional, Leroy, V., additional, Poynard, T., additional, Causse, X., additional, Chazouillères, O., additional, Valla, D., additional, Zanditenas, D., additional, Renou, C., additional, Trinchet, J.-C., additional, Paupard, T., additional, Ouzan, D., additional, Guyader, D., additional, Fontanges, T., additional, Hanslik, B., additional, De Lédinghen, V., additional, and Denis, J., additional

Published
2015
Full Text
View/download PDF

38. P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir)

Author

Nahon, P., primary, Bourcier, V., additional, Layese, R., additional, Talmat, N., additional, Allam, S., additional, Marcellin, P., additional, Guyader, D., additional, Pol, S., additional, Larrey, D., additional, Zoulim, F., additional, Roulot, D., additional, de Lédinghen, V., additional, Ouzan, D., additional, Zarski, J.-P., additional, Trinchet, J.-C., additional, and Roudot-Thoraval, F., additional

Published
2015
Full Text
View/download PDF

39. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

Author

Watkinson, A., Avajon, Y., Gruenberger, T., Pomoni, M., Schuchmann, M., Mueller, C., Lencioni, R., Lammer, J., Langenberger, H., Schoder, M., Funovics, M., Loewe, C., Moyses, J., Grunberger, T., Waldenberger, P., Chemelli, A., Graziadei, I., Vogl, T., Khan, V., Hammerstingl, R., Lee, C., Eichler, K., Pitton, M., Klockner, R., Duber, C., Otto, G., Worns, M. A., Greten, T., Kirchhoff, T., Rosenthal, H., Lotz, J., Huppert, P., Wietholtz, H., Limmer, A., Pilleul, F., Ficarelli, S., Mennesson, N., Rauscher, N., Dumortier, J., Guillaud, O., Vilgrain, V., Sibert, A., Chevallier, P., Novellas, S., Tran, A., Ouzan, D., Gugenheim, J., Sergent, G., Otal, P., Joffre, F., Auriol, J., Peron, J. M., Benhamou, Y., Ratzui, V., Clluzel, P., Baere, T., Deschamps, F., Roo, P., Ajavon, Y., Awad, S., Bellin, M. F., Samuel, D., Castaing, D., Adam, R., Vallee, J. C., Saliba, F., Azoulay, D., Denys, A., Triller, J., Kickuth, R., Terraz, S., Becker, C. D., Majno, P., Spahr, L., Pfammatter, T., Weishaupt, D., Muellhaupt, B., Malagari, K., Maria, P., Kelekis, D., Kelekis, N., Kelekis, A., Emmanouil, E., Pisa University Hospital and School of Medicine, Department of Chemistry, North Carolina Raleigh, North Carolina State University [Raleigh] (NC State), University of North Carolina System (UNC)-University of North Carolina System (UNC), Centre de Recherche et d'Application en Traitement de l'Image et du Signal (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Supérieure Chimie Physique Électronique de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'hépatologie, Hospices Civils de Lyon (HCL), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d'investigation clinique en cancérologie (CI2C), Animal et gestion intégrée des risques (UPR AGIRs), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Institut Arnault Tzanck, Service de Chirurgie Digestive et Transplantation Hépatique, Hôpital Archet II, Service de Radiologie [Rangueil / Larrey], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagerie thérapeutique (radiologie interventionnelle), Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), ETH Hoenggerberg, Institute of Geophysics, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hépato-Biliaire, Stadtspital Triemli Zürich, Université de Lyon-Université de Lyon-École Supérieure de Chimie Physique Électronique de Lyon (CPE)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Chirurgie Digestive / Centre de Transplantation Hépatique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), and Ratiney, Helene

Subjects
[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

40. P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

Author

Asselah, T., primary, Jensen, D.M., additional, Foster, G.R., additional, Sulkowski, M.S., additional, Ouzan, D., additional, Morano, L., additional, Buynak, R., additional, Agarwal, K., additional, Hassanein, T., additional, Forton, D., additional, Cho, M., additional, Genné, D., additional, Kaita, K., additional, Maieron, A., additional, Preotescu, L., additional, Sarrazin, C., additional, Zehnter, E., additional, Streinu-Cercel, A., additional, Stern, J.O., additional, Datsenko, Y., additional, Drulak, M., additional, Voss, F., additional, Quinson, A.-M., additional, and Ferenci, P., additional

Published
2014
Full Text
View/download PDF

41. P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES

Author

Causse, X., primary, Pageaux, G.-P., additional, Zoulim, F., additional, Larrey, D., additional, Ouzan, D., additional, Truchi, R., additional, Pauwels, A., additional, Guyader, D., additional, De Ledinghen, V., additional, Tilliet, V., additional, Cadranel, J.-F., additional, Stern, C., additional, Libert, O., additional, and Marcellin, P., additional

Published
2014
Full Text
View/download PDF

42. P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

Author

Asselah, T., primary, Jensen, D.M., additional, Foster, G.R., additional, Sulkowski, M.S., additional, Ouzan, D., additional, Morano, L., additional, Buynak, R., additional, Agarwal, K., additional, Hassanein, T., additional, Forton, D., additional, Negro, F., additional, Genné, D., additional, Kaita, K., additional, Maieron, A., additional, Preotescu, L., additional, Sarrazin, C., additional, Zehnter, E., additional, Romero-Gómez, M., additional, Stern, J.O., additional, Quinson, A.-M., additional, Drulak, M., additional, Garcia, M., additional, Voss, F., additional, Böcher, W., additional, and Ferenci, P., additional

Published
2014
Full Text
View/download PDF

43. P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

Author

Pageaux, G.-P., primary, Zoulim, F., additional, Causse, X., additional, Larrey, D., additional, Ouzan, D., additional, Truchi, R., additional, Pauwels, A., additional, Guyader, D., additional, De Ledinghen, V., additional, Zarski, J.-P., additional, Cadranel, J.-F., additional, Tilliet, V., additional, Stern, C., additional, Libert, O., additional, and Marcellin, P., additional

Published
2014
Full Text
View/download PDF

45. SAT-007 - The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Author

Bureau, C., Thabut, D., Layese, R., Bourcier, V., Corvy, L., Petrov-Sanchez, V., Marcellin, P., Guyader, D., Pol, S., Larrey, D., Zoulim, F., Roulot, D., De Ledinghen, V., Ouzan, D., Tran, A., Bronowicki, J.-P., Riachi, G., Cales, P., Peron, J.-M., Alric, L., Bourliere, M., Mathurin, P., Zarski, J.-P., Roudot-Thoraval, F., and Nahon, P.

Published
2016
Full Text
View/download PDF

46. FRI-137 - Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

Author

Marcellin, P., Xie, Q., Paik, S.W., Flisiak, R., Piratvisuth, T., Petersen, J., Asselah, T., Cornberg, M., Ouzan, D., Foster, G.R., Papatheodoridis, G.V., Messinger, D., Regep, L., Bakalos, G., Alshuth, U., and Wedemeyer, H.

Published
2016
Full Text
View/download PDF

50. THU-352 - Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

Author

Allaire, M., Bourcier, V., Layese, R., Corvi, L., Petrov-Sanchez, V., Marcellin, P., Guyader, D., Larrey, D., De Lédinghen, V., Ouzan, D., Zoulim, F., Roulot, D., Tran, A., Bronowicki, J.-P., Zarski, J.-P., Riachi, G., Calès, P., Péron, J.-M., Alric, L., Bourlière, M., Mathurin, P., Nahon, P., and Roudot-Thoraval, F.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results